1036389-86-2

Basic information

• Product Name: 5-AMino-2-broMo-4-fluorobenzoic Acid Methyl Ester
• Synonyms: 5-AMino-2-broMo-4-fluorobenzoic Acid Methyl Ester
• CAS NO: 1036389-86-2
• Molecular Formula: C₈H₇BrFNO₂
• Molecular Weight: 248.0490832
• Product Categories: Aromatics, Miscellaneous Reagents
• Mol File: 1036389-86-2.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-AMino-2-broMo-4-fluorobenzoic Acid Methyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMino-2-broMo-4-fluorobenzoic Acid Methyl Ester(1036389-86-2)
• EPA Substance Registry System: 5-AMino-2-broMo-4-fluorobenzoic Acid Methyl Ester(1036389-86-2)

Safety Data

• Hazardous Substances Data: 1036389-86-2(Hazardous Substances Data)

Usage

Uses

5-Amino-2-bromo-4-fluorobenzoic Acid Methyl Ester is used in the suthesis of lactam amino acid derivatives with anti-coagulant activity.

Upstream product

• 1006-41-3 2-bromo-4-fluorobenzoic acid 
• 85953-31-7 2-bromo-4-fluoro-5-nitrobenzoic acid methyl ester 

Downstream Products

• 1036389-90-8 6-amino-5-fluoro-isoindolin-1-one 
• 1036389-92-0 C₁₈H₁₇FN₂O₅ 
• 1036389-88-4 5-amino-2-cyano-4-fluorobenzoate methyl ester 

Relevant articles and documents

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors

Inhibitors of Factor VIIa (FVIIa), a serine protease in the clotting cascade, have shown strong antithrombotic efficacy in preclinical thrombosis models with minimal bleeding liabilities. Discovery of potent, orally active FVIIa inhibitors has been largely unsuccessful because known chemotypes have required a highly basic group in the S1 binding pocket for high affinity. A recently reported fragment screening effort resulted in the discovery of a neutral heterocycle, 7-chloro-3,4-dihydroisoquinolin-1(2H)-one, that binds in the S1 pocket of FVIIa and can be incorporated into a phenylglycine FVIIa inhibitor. Optimization of this P1 binding group led to the first series of neutral, permeable FVIIa inhibitors with low nanomolar potency.

A kind of diaryl hydanto?n derivatives, its preparation method, pharmaceutical composition and application

Provided are a compound as represented by formula I, or pharmaceutically acceptable salt, solvate, precursor drug, stereoisomer, tautomer, polymorph or metabolite thereof, pharmaceutical composition containing same, and uses thereof in the preparation of drugs for treating androgen receptor related diseases.